|
Digital health platform MedPal AI Ltd on Friday revealed plans for a late-August debut on the AIM market in London. The London-based technology firm aggregates health data from smartphones and wearable devices to provide AI-generated wellness support. MedPal is targeting a market capitalisation of £16.0 million upon listing and expects to raise £1.6 million by issuing around 403 million shares at 4 pence each in the initial public offering. The company operates on a director-to-consumer, subscription-fee basis. It runs an application collecting customer data from third-party apps and devices such as Apple Health, FitBit, Garmin and Google Fit. MedPal specifies that its services are ‘non-clinical’ and that it ‘does not provide medical advice but signposts users to appropriate care when needed’. The firm has a partnership with the UK branch of the Epassi Group, a Helsinki-based employee health benefits platform, which will offer its users a free 12-month MedPal membership. MedPal aims ‘to expand quickly into other territories including the US’ through business-to-business licensing deals and insurance channel bundling. MedPal’s majority shareholder is Chief Executive Jason Drummond, who owns 46.8% of the company, which is expected to dilute to 42.17% upon admission to AIM. Director Justin Drummond’s 10.33% stake will dilute to 9.30%, and minority shareholder Marie Juste’s 3.44% will become 3.10%. The IPO is expected in late August. MedPal has appointed Clear Capital Markets Ltd as broker and Cairn Financial Advisers LLP as nominated advisor. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
